Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Current Valuation Ratios
| AmerisourceBergen Corp. | Abbott Laboratories | Elevance Health Inc. | Intuitive Surgical Inc. | Medtronic PLC | UnitedHealth Group Inc. | Health Care Equipment & Services | Health Care | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||
| Current share price (P) | $191.43 | ||||||||||
| No. shares of common stock outstanding | 202,174,856 | ||||||||||
| Growth rate (g) | 125.84% | ||||||||||
| Earnings per share (EPS) | $8.40 | ||||||||||
| Next year expected EPS | $18.98 | ||||||||||
| Operating profit per share | $11.70 | ||||||||||
| Sales per share | $1,180.10 | ||||||||||
| Book value per share (BVPS) | $-1.05 | ||||||||||
| Valuation Ratios (Price Multiples) | |||||||||||
| Price to earnings (P/E) | 22.78 | 29.16 | 16.24 | 54.96 | 27.12 | 29.29 | 23.39 | 32.02 | |||
| Price to next year expected earnings | 10.09 | 27.04 | 14.52 | 48.19 | 26.76 | 26.10 | 20.98 | 28.01 | |||
| Price-earnings-growth (PEG) | 0.18 | 3.72 | 1.37 | 3.91 | 19.80 | 2.39 | 2.03 | 2.24 | |||
| Price to operating profit (P/OP) | 16.36 | 23.62 | 13.99 | 53.29 | 20.14 | 18.62 | 17.81 | 25.02 | |||
| Price to sales (P/S) | 0.16 | 4.29 | 0.47 | 15.60 | 3.58 | 0.80 | 1.65 | 4.69 | |||
Based on: 10-K (reporting date: 2022-09-30).
If the company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.
Otherwise, if the company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.
Historical Valuation Ratios (Summary)
Based on: 10-K (reporting date: 2022-09-30), 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30).
The valuation multiples for AmerisourceBergen Corp. exhibit a combination of significant volatility in earnings-based metrics and high stability in revenue-based metrics over the period from 2017 to 2022.
- Price to Earnings (P/E) Ratio
- A period of substantial fluctuation is observed, beginning with a peak of 47.54 in 2017, followed by a sharp correction to 11.36 in 2018. Subsequent years show a moderate recovery and stabilization, with the ratio fluctuating between 16.71 and 21.14 from 2019 to 2022, suggesting a normalization of investor expectations regarding earnings.
- Price to Operating Profit (P/OP) Ratio
- The valuation relative to operating profit demonstrates greater stability than the P/E ratio. The multiple remained within a range of 10.93 to 16.34 throughout the observed period, indicating that the market valuation of the company's core operations remained relatively consistent despite fluctuations in net income.
- Price to Sales (P/S) Ratio
- An exceptionally stable and low trend is evident, with the ratio holding steady at approximately 0.10 to 0.11 for most of the period. A slight upward trend emerged in the final two years, reaching 0.14 by September 30, 2022, which reflects a marginal increase in the market premium attributed to each dollar of revenue.
- Price to Book Value (P/BV) Ratio
- The ratio remained relatively consistent between 6.28 and 8.39 from 2017 to 2019. However, a significant anomaly occurred in 2021, where the ratio surged to 115.23. This extreme increase suggests a substantial reduction in the book value of equity relative to the market price, often associated with aggressive share buybacks or significant accounting adjustments.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Price to Earnings (P/E)
| Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | ||
|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 205,668,628 | 208,133,361 | 204,249,747 | 205,922,186 | 211,933,493 | 218,082,051 | |
| Selected Financial Data (US$) | |||||||
| Net income (loss) attributable to AmerisourceBergen Corporation (in thousands) | 1,698,820) | 1,539,932) | (3,408,716) | 855,365) | 1,658,405) | 364,484) | |
| Earnings per share (EPS)2 | 8.26 | 7.40 | -16.69 | 4.15 | 7.83 | 1.67 | |
| Share price1, 3 | 164.71 | 123.66 | 101.90 | 87.81 | 88.87 | 79.46 | |
| Valuation Ratio | |||||||
| P/E ratio4 | 19.94 | 16.71 | — | 21.14 | 11.36 | 47.54 | |
| Benchmarks | |||||||
| P/E Ratio, Competitors5 | |||||||
| Abbott Laboratories | 26.76 | 29.13 | — | — | — | — | |
| Elevance Health Inc. | 19.20 | 18.13 | — | — | — | — | |
| Intuitive Surgical Inc. | 64.99 | 59.94 | — | — | — | — | |
| Medtronic PLC | 23.38 | 46.56 | — | — | — | — | |
| UnitedHealth Group Inc. | 22.46 | 26.03 | — | — | — | — | |
| P/E Ratio, Sector | |||||||
| Health Care Equipment & Services | 24.26 | 28.98 | — | — | — | — | |
| P/E Ratio, Industry | |||||||
| Health Care | 21.22 | 21.55 | — | — | — | — | |
Based on: 10-K (reporting date: 2022-09-30), 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30).
1 Data adjusted for splits and stock dividends.
2 2022 Calculation
EPS = Net income (loss) attributable to AmerisourceBergen Corporation ÷ No. shares of common stock outstanding
= 1,698,820,000 ÷ 205,668,628 = 8.26
3 Closing price as at the filing date of AmerisourceBergen Corp. Annual Report.
4 2022 Calculation
P/E ratio = Share price ÷ EPS
= 164.71 ÷ 8.26 = 19.94
5 Click competitor name to see calculations.
The share price exhibited a consistent upward trajectory from September 30, 2017, to September 30, 2022, increasing from 79.46 US$ to 164.71 US$. This steady appreciation in market valuation occurred despite significant volatility in earnings per share (EPS), which experienced a sharp contraction and subsequent recovery during the analyzed period.
- Earnings Per Share (EPS) Volatility
- Earnings exhibited substantial fluctuations, beginning at 1.67 US$ in 2017 and peaking at 7.83 US$ in 2018. A significant downturn occurred by September 30, 2020, where EPS fell to -16.69 US$, representing a severe temporary impairment of profitability. However, a strong recovery followed, with earnings returning to positive territory at 7.40 US$ in 2021 and reaching a period high of 8.26 US$ in 2022.
- Price-to-Earnings (P/E) Ratio Dynamics
- The P/E ratio demonstrated inverse correlation with EPS volatility. An elevated ratio of 47.54 was recorded in 2017, coinciding with lower earnings. This compressed significantly to 11.36 in 2018 as earnings surged. Following a rise to 21.14 in 2019, the ratio became non-calculable in 2020 due to negative earnings. In the post-recovery phase of 2021 and 2022, the P/E ratio stabilized between 16.71 and 19.94, suggesting a more consistent market valuation of the company's earnings power.
- Valuation Trend Analysis
- A divergence is observable between the share price and the P/E ratio. While the share price more than doubled over the six-year period, the P/E ratio moved from an extreme high toward a more moderate range. This indicates that the increase in share price was driven not by expanding valuation multiples, but rather by the recovery and growth of fundamental earnings per share following the 2020 deficit.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Price to Operating Profit (P/OP)
| Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | ||
|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 205,668,628 | 208,133,361 | 204,249,747 | 205,922,186 | 211,933,493 | 218,082,051 | |
| Selected Financial Data (US$) | |||||||
| Operating income (loss) (in thousands) | 2,366,378) | 2,354,197) | (5,135,354) | 1,111,923) | 1,443,685) | 1,060,342) | |
| Operating profit per share2 | 11.51 | 11.31 | -25.14 | 5.40 | 6.81 | 4.86 | |
| Share price1, 3 | 164.71 | 123.66 | 101.90 | 87.81 | 88.87 | 79.46 | |
| Valuation Ratio | |||||||
| P/OP ratio4 | 14.32 | 10.93 | — | 16.26 | 13.05 | 16.34 | |
| Benchmarks | |||||||
| P/OP Ratio, Competitors5 | |||||||
| Abbott Laboratories | 22.18 | 24.45 | — | — | — | — | |
| Elevance Health Inc. | 15.05 | 15.70 | — | — | — | — | |
| Intuitive Surgical Inc. | 54.49 | 56.11 | — | — | — | — | |
| Medtronic PLC | 20.48 | 37.44 | — | — | — | — | |
| UnitedHealth Group Inc. | 15.89 | 18.77 | — | — | — | — | |
| P/OP Ratio, Sector | |||||||
| Health Care Equipment & Services | 18.47 | 22.66 | — | — | — | — | |
| P/OP Ratio, Industry | |||||||
| Health Care | 16.58 | 18.20 | — | — | — | — | |
Based on: 10-K (reporting date: 2022-09-30), 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30).
1 Data adjusted for splits and stock dividends.
2 2022 Calculation
Operating profit per share = Operating income (loss) ÷ No. shares of common stock outstanding
= 2,366,378,000 ÷ 205,668,628 = 11.51
3 Closing price as at the filing date of AmerisourceBergen Corp. Annual Report.
4 2022 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 164.71 ÷ 11.51 = 14.32
5 Click competitor name to see calculations.
Between September 30, 2017, and September 30, 2022, the share price exhibited a consistent upward trajectory, rising from 79.46 to 164.71. During this same period, operating profit per share showed significant volatility, most notably a severe contraction in 2020 where it reached -25.14, before rebounding to 11.51 by 2022.
- Price to Operating Profit (P/OP) Fluctuations
- The P/OP ratio displayed a non-linear trend, starting at 16.34 in 2017 and decreasing to 13.05 in 2018, before returning to 16.26 in 2019. Due to the operating loss recorded in 2020, the ratio was not applicable for that period. In 2021, the ratio reached its lowest observed value of 10.93, subsequently increasing to 14.32 in 2022.
- Relationship Between Market Value and Profitability
- A divergence is noted between the share price and the P/OP ratio in the latter years of the period. While the share price reached its peak in 2022, the P/OP ratio remained below the levels observed in 2017 and 2019. This suggests that the increase in market valuation was supported by a substantial increase in fundamental operating profitability, as the operating profit per share in 2022 was more than double the amount recorded in 2017.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Price to Sales (P/S)
| Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | ||
|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 205,668,628 | 208,133,361 | 204,249,747 | 205,922,186 | 211,933,493 | 218,082,051 | |
| Selected Financial Data (US$) | |||||||
| Revenue (in thousands) | 238,587,006) | 213,988,843) | 189,893,926) | 179,589,121) | 167,939,635) | 153,143,826) | |
| Sales per share2 | 1,160.06 | 1,028.13 | 929.71 | 872.12 | 792.42 | 702.23 | |
| Share price1, 3 | 164.71 | 123.66 | 101.90 | 87.81 | 88.87 | 79.46 | |
| Valuation Ratio | |||||||
| P/S ratio4 | 0.14 | 0.12 | 0.11 | 0.10 | 0.11 | 0.11 | |
| Benchmarks | |||||||
| P/S Ratio, Competitors5 | |||||||
| Abbott Laboratories | 4.25 | 4.78 | — | — | — | — | |
| Elevance Health Inc. | 0.74 | 0.81 | — | — | — | — | |
| Intuitive Surgical Inc. | 13.81 | 17.89 | — | — | — | — | |
| Medtronic PLC | 3.72 | 5.57 | — | — | — | — | |
| UnitedHealth Group Inc. | 1.40 | 1.58 | — | — | — | — | |
| P/S Ratio, Sector | |||||||
| Health Care Equipment & Services | 1.71 | 2.07 | — | — | — | — | |
| P/S Ratio, Industry | |||||||
| Health Care | 3.11 | 3.28 | — | — | — | — | |
Based on: 10-K (reporting date: 2022-09-30), 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30).
1 Data adjusted for splits and stock dividends.
2 2022 Calculation
Sales per share = Revenue ÷ No. shares of common stock outstanding
= 238,587,006,000 ÷ 205,668,628 = 1,160.06
3 Closing price as at the filing date of AmerisourceBergen Corp. Annual Report.
4 2022 Calculation
P/S ratio = Share price ÷ Sales per share
= 164.71 ÷ 1,160.06 = 0.14
5 Click competitor name to see calculations.
The financial performance from 2017 to 2022 is characterized by a consistent expansion in both revenue generation per share and market valuation. While top-line efficiency grew steadily throughout the period, the market's valuation of the company accelerated more significantly in the later years.
- Sales per Share Growth
- A consistent upward trajectory is observed in sales per share, which increased from 702.23 US$ in 2017 to 1,160.06 US$ in 2022. This steady climb indicates a robust and uninterrupted growth in revenue relative to the number of shares outstanding.
- Share Price Appreciation
- The share price rose from 79.46 US$ in 2017 to 164.71 US$ in 2022. The growth was relatively moderate between 2017 and 2019, followed by a more aggressive acceleration from 2020 onward, reflecting increased investor confidence or improved market conditions.
- Price-to-Sales (P/S) Ratio Trends
- The P/S ratio remained highly compressed and stable, fluctuating minimally between 0.10 and 0.12 from 2017 to 2021. This stability suggests a consistent valuation model based on high-volume, low-margin operations. A notable shift occurred in 2022, when the ratio rose to 0.14, indicating that the share price began to grow at a faster rate than the sales per share, resulting in a slight expansion of the valuation multiple.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Price to Book Value (P/BV)
| Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | ||
|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 205,668,628 | 208,133,361 | 204,249,747 | 205,922,186 | 211,933,493 | 218,082,051 | |
| Selected Financial Data (US$) | |||||||
| Total AmerisourceBergen Corporation stockholders’ equity (deficit) (in thousands) | (211,559) | 223,354) | (1,018,924) | 2,878,917) | 2,932,824) | 2,064,461) | |
| Book value per share (BVPS)2 | -1.03 | 1.07 | -4.99 | 13.98 | 13.84 | 9.47 | |
| Share price1, 3 | 164.71 | 123.66 | 101.90 | 87.81 | 88.87 | 79.46 | |
| Valuation Ratio | |||||||
| P/BV ratio4 | — | 115.23 | — | 6.28 | 6.42 | 8.39 | |
| Benchmarks | |||||||
| P/BV Ratio, Competitors5 | |||||||
| Abbott Laboratories | 5.06 | 5.75 | — | — | — | — | |
| Elevance Health Inc. | 3.19 | 3.07 | — | — | — | — | |
| Intuitive Surgical Inc. | 7.78 | 8.59 | — | — | — | — | |
| Medtronic PLC | 2.24 | 3.26 | — | — | — | — | |
| UnitedHealth Group Inc. | 5.81 | 6.27 | — | — | — | — | |
| P/BV Ratio, Sector | |||||||
| Health Care Equipment & Services | 4.46 | 5.01 | — | — | — | — | |
| P/BV Ratio, Industry | |||||||
| Health Care | 5.26 | 5.48 | — | — | — | — | |
Based on: 10-K (reporting date: 2022-09-30), 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30).
1 Data adjusted for splits and stock dividends.
2 2022 Calculation
BVPS = Total AmerisourceBergen Corporation stockholders’ equity (deficit) ÷ No. shares of common stock outstanding
= -211,559,000 ÷ 205,668,628 = -1.03
3 Closing price as at the filing date of AmerisourceBergen Corp. Annual Report.
4 2022 Calculation
P/BV ratio = Share price ÷ BVPS
= 164.71 ÷ -1.03 = —
5 Click competitor name to see calculations.
The analysis of valuation multiples between 2017 and 2022 reveals a significant divergence between the market price of the equity and the underlying book value. While the market valuation trended upward throughout the period, the book value per share experienced extreme volatility and a substantial decline, rendering the Price to Book Value (P/BV) ratio highly unstable in later years.
- Share Price Trend
- A consistent upward trajectory is observed in the share price, which rose from 79.46 US$ in 2017 to 164.71 US$ in 2022. This growth indicates sustained market demand and an increasing valuation of the company's equity by investors.
- Book Value per Share (BVPS) Volatility
- The BVPS initially increased from 9.47 US$ in 2017 to a peak of 13.98 US$ in 2019. Subsequently, a sharp decline occurred, with the value falling to -4.99 US$ in 2020. Although a marginal recovery to 1.07 US$ was recorded in 2021, the value returned to a negative position of -1.03 US$ by 2022, indicating a severe erosion of the company's equity base.
- Price to Book Value (P/BV) Ratio Analysis
- From 2017 to 2019, the P/BV ratio showed a gradual decline from 8.39 to 6.28, suggesting a stabilizing relationship between price and book value. However, the ratio became mathematically inapplicable in 2020 and 2022 due to negative book values. The spike to 115.23 in 2021 is identified as a technical anomaly resulting from a very low positive BVPS (1.07 US$) paired with a high share price, rather than an increase in fundamental valuation.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?